Lonidamine

Lonidamine is a derivative of indazole-3-carboxylic acid, which for a long time, has been known to inhibit aerobic glycolysis in cancer cells. It seems to enhance aerobic glycolysis in normal cells, but suppress glycolysis in cancer cells. This is most likely through the inhibition of the mitochondrially bound hexokinase. Later studies in Ehrlich ascites tumor cells showed that lonidamine inhibits both respiration and glycolysis leading to a decrease in cellular ATP.^[1]

Lonidamine

Clinical data
ATC code	L01XX07 (WHO)
Identifiers
IUPAC name 1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid
CAS Number	50264-69-2 Y
PubChem CID	39562
ChemSpider	36170 N
UNII	U78804BIDR
KEGG	D07257 Y
ChEBI	CHEBI:50138
CompTox Dashboard (EPA)	DTXSID5020782
ECHA InfoCard	100.051.356
Chemical and physical data
Formula	C15H10Cl2N2O2
Molar mass	321.16 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O
InChI InChI=1S/C15H10Cl2N2O2/c16-10-6-5-9(12(17)7-10)8-19-13-4-2-1-3-11(13)14(18-19)15(20)21/h1-7H,8H2,(H,20,21) N Key:WDRYRZXSPDWGEB-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Clinical trials of lonidamine in combination with other anticancer agents for a variety of cancers has begun. This is due to its proven ability to inhibit energy metabolism in cancer cells, and to enhance the activity of anticancer agents.^[1]

Lonidamine has been used in the treatment of brain tumours in combination with radiotherapy and temozolomide.^[2] An in-vitro study showed that a combination of temozolomide and lonidamine at clinically achievable, low plasma concentrations, could inhibit tumour growth, and lonidamine could reduce the dose of temozolomide required for radiosensitization of brain tumours.^[2]

A derivative of lonidamine, gamendazole, is in testing as a possible male contraceptive pill.^[3]